This disclosure relates generally to cell sampling and screening for use in detecting abnormal tissues in the body, for example in the cervix. More specifically, this disclosure relates to systems and methods whereby clusters of cells are collected in a manner where the spatial arrangement of the collected clusters of cells is preserved, and the biological properties of such clusters are examined with respect to the expression of two or more features.
It is often necessary to collect various cell samples from patients for the purposes of screening for, detecting, and ultimate treatment of, a number of diseases and abnormalities. One of the major reasons for the collection of cellular samples is for the purpose of screening patients for cancer. For example, urine, sputum, breast nipple and fine needle aspirates, and exfoliated cells of the uterine cervix are screened by cytotechnicians and pathologists for the presence of abnormal cells suggestive of the presence of a solid tumor. When such suspicious cells are found, a more definitive diagnosis is reached by removing a sample of the tissue where a lesion is suspected, and submitting the sample for review by a pathologist.
A major issue with any screening test, or preliminary diagnostic test, is that it must be sensitive enough to detect disease, but specific enough not to classify unaffected individuals at such a high frequency as to present an emotional or physical burden. This is especially true for those screening tests, such as cervical cytology (commonly termed the Pap test), which are routinely applied to large populations without regard to a heightened index of suspicion of the presence of disease.
It is generally accepted that diagnosis of cancer at its earliest stages affords the greatest opportunity for effective treatment. A corollary to this is that early diagnosis of a solid tumor corresponds to recognition of localized abnormalities, which at the cellular level are not that different from the surrounding tissue. This presents a challenge for screening of cellular samples where all context and comparison to neighboring cells is lost. One approach to this problem is to concentrate upon elements, i.e. groups of cells, which more closely approximate intact tissue elements. In fact, the presence of such clusters of cells, in and of itself, can be considered to be suggestive of a pre-cancerous or cancerous condition. However, it is also the case that normal tissue elements can be represented as cell clusters in samples collected for cytologic analysis.
Preneoplastic lesions present unique biological features. Dysplasia, the early phase of neoplastic progression, involves cells that are individually minimally different from normal cells present in the same tissue. The major difference between a dysplastic lesion and normal tissue elements undergoing changes in shape (metaplasia) or actively proliferating (hyperplasia) is an imbalance in the fractions of cells expressing characteristic proteins involving abnormal cell growth and turnover. It is well recognized by pathologists, who examine intact tissues, that the admixture of morphological (e,g, mitotic figures) or biochemical (e.g. Ki-67 proliferation antigen) markers of normal growth and function with morphological (e.g. apoptotic bodies) or biochemical (e.g. activated caspase 3) indicators of cell turnover by the process of apoptosis, is characteristic of dysplasia.
Conventional sampling methods utilized in current screening procedures acquire cells from a lesion, but then disperse these cells into a typically much larger number of normal cells obtained from outside of the boundaries of the lesion. This dispersion results in the evaluation of a sample being an exercise in the detection of a rare event; that is, finding one or a few abnormal cells within a background consisting of a very large number (e.g. 50,000-300,000) of normal cells. Furthermore, and perhaps most significantly, dispersion eliminates the information that can be gained from determining the biological characteristics of small areas that might represent preneoplastic lesions. This essential information is present in the relationship among cells, and is not apparent by examining individual cells in isolation from adjacent cells within a tissue. Dispersion also precludes using the sample to determine the location of the lesion on the patient.
Therefore, it would also be desirable to incorporate the unique biological features of preneoplastic lesions with a means to collect and analyze clusters of cells, and screen cellular samples for the presence of cell clusters indicative of dysplasia in the sampled tissue.
The invention relates to systems and methods to screen cellular samples for the presence of cell clusters indicative of dysplasia in the sampled tissue. Clusters of cells are interrogated for two or more biological markers that do not, or rarely, occur in the same cell during normal cellular growth, development and function, to indicate the existence of cells that are part of a local area where a pre-neoplastic or neoplastic lesion (hereinafter “dysplasia”) may be present. The relationship among cells is maintained while interrogating the clusters of cells to facilitate the examination and determination of the existence of possible dysplasia of the tissue.
The concepts described herein can be implemented using biological markers that are not, or rarely, co-expressed in the same cell and the expression of which becomes imbalanced in dysplasia. The two or more markers that are screened can result from an imbalance in the fractions of cells expressing characteristic proteins involving abnormal cell growth and turnover. For example, the admixture of morphological (e,g, mitotic figures) or biochemical (e.g. Ki-67 proliferation antigen) markers of normal growth and function with morphological (e.g. apoptotic bodies) or biochemical (e.g. activated caspase 3) indicators of cell turnover by the process of apoptosis, is characteristic of dysplasia.
The concepts described herein can be used to screen for dysplasia in a number of regions of the body, for example from the cervix, the bladder, the lungs, the colon, the ovaries, and breasts. The clusters of cells can be analyzed as they naturally occur or they can be analyzed as they naturally occur or they can be collected from tissue, urine, induced sputum, breast secretions, cells washed from ovaries, and the like using a suitable collector.
The cell collector is preferably designed to enhance the capability of the collector to maintain the integrity of cellular clusters or clumps, and to facilitate transfer of the collected clusters of cells onto a receiving structure, for example a slide. In one embodiment, a combination of the material of the collector, the texture of the collection surface of the collector, and the use of expansion and rotation of the collector during collection facilitate the collection of the clusters of cells. Preferably, the collector can be expanded during transfer such that the cell clusters obtained from the endo- and ecto-cervical regions end up on a generally common plane for subsequent transfer to the receiving structure. Preferably, clusters of cells are transferred from the collector to the receiving structure in such a way as to retain the spatial relationships that existed between the cells in the clusters prior to sampling. Orientation marks on the collector and the receiving structure assist in maintaining the spatial relationship during transfer.
The collector is expanded during collection as well as during transfer of the cells. Expansion during collection and transfer can occur through the use of air, by a mechanical expansion system, or through a combination of air and a mechanical system.
FIGS. 1A-C illustrate the general features of a cervical analysis system utilizing the concepts of the present invention.
FIGS. 5A-C are cross sectional views of the tip region of the cell collector illustrating expansion of the cell collector tip during cell cluster collection.
FIGS. 6A-C illustrate the steps of cell cluster collection from a cervix using the cell collector.
FIGS. 7A-K illustrate the process of cell cluster transfer using the cell collector, with colored marker and marking fluid simulating collected clusters of cells.
FIGS. 9A-C are views of a touch prep of cervical cells after labeling with markers.
FIGS. 13A-C are detailed views of the tip region of the cell collector of
FIGS. 14A-C illustrates another example of a tip of a cell collector.
FIGS. 15A-B illustrate another mechanism for achieving cell cluster transfer.
FIGS. 20A-C illustrate a mechanism for rotating the cell collector during collection.
Cancer is a disease of tissue not cells. Diagnosis of solid tumors by pathologists depends on recognition of the architecture of lesions, specifically how cells within a lesion differ from surrounding normal cells. The criteria used have included morphology, cytochemical stains to recognize cellular structures, and the use of antibodies and nucleic acid probes to determine the patterns of expression and organization of the cellular genetic material.
Neoplastic progression corresponds to accretion of genetic and epigenetic changes which render cells within the nascent tumor increasingly more able to proliferate without responding to normal regulatory signals and factors, invade surrounding tissue elements, become vascularized, and metastasize. However, at the earliest stage of this process, dysplastic lesions arise from the clonal expansion of a precursor cell which was minimally different from the surrounding normal cells.
Screening for cancer at its earliest stages requires recognition of rare dysplastic cells which have not clonally expanded to the point where the number of such cells is physically apparent or clinically manifested in symptoms. The means for recognition of such cells are limited with regard to morphological and biological criteria by the very nature of the minimal difference between these cells and the adjacent normal cells.
A concept of the invention is that a dysplastic precancerous lesion can be distinguished from normal tissue elements by analyzing clusters of cells to look for two or more biological markers that are rarely co-expressed in the same cell at any one point in normal tissue. For example, clusters of cells can be interrogated for two or more biological markers that indicate the existence of individual cells that are part of a local area where dysplasia may be present. The following description and examples refer to growth and apoptosis as the two or more biological markers for purposes of explaining the concepts. However, it is to be realized that two or more other biological markers that are rarely co-expressed in the same cell can be used, or could be used in conjunction with cell growth and apoptosis as markers.
The concepts described herein can be used to screen for dysplastic precancerous lesions from a number of regions of the body. For purposes of explanation, the inventive concepts will be discussed below with respect to the collection of clusters of cells from a cervix to screen for cervical cancer. However, it is to be realized that the inventive concepts can be used to screen for dysplasia by examining clusters of cells from other regions of the body, for example the bladder to screen for bladder cancer, the lungs to screen for lung cancer, the colon to screen for colon cancer, and the ovaries to screen for ovarian cancer. The clusters of cells can be collected from tissue, urine, induced sputum, cells washed from ovaries, and the like.
The clusters of cells are collected using a collector that is designed to enhance the ability of the collector to pick-up clusters or clumps of cells, and to facilitate transfer of the collected clusters of cells onto a receiving structure, for example a slide. In one embodiment, a combination of the material of the collector, the texture of the collection surface of the collector, and the use of expansion and rotation of the collector during collection facilitate the collection of cell clusters. Preferably, clusters of cells are transferred from the collector to the receiving structure in such a way as to retain the spatial relationships that existed between the cells in the clusters prior to sampling. Orientation marks on the collector and the receiving structure assist in maintaining the spatial relationship during transfer.
In the case of dysplastic lesions on the cervix, a cervical analysis system according to the concepts of the invention encompasses a cell collector, a receiving structure to which collected clusters of cells are transferred from the collector, reagents and a scanner device which together (1) obtain clusters of cells from the endocervical and ectocervical areas of the cervix; (2) maintain the spatial relationship among the collected cell clusters on the collector and when transferred to the receiving structure; (3) examine the molecular properties of the cell clusters to establish if there is any evidence of abnormality in the cells; and (4) do this in a manner that allows a clinician to ascertain where on the cervix a dysplastic lesion might be present.
The cervical analysis system is one embodiment of an approach to the screening of cell clusters present in specimens in order to identify dysplastic lesions by virtue of the application of biomarkers which reveal a characteristic imbalance in the biological properties of adjacent cells.
FIGS. 1A-C illustrate the concepts of cell cluster collection from a uterine cervix 50.
In addition, the collector 100 has a visible orientation mark 106 to permit the individual collecting the clusters of cells to orient the collector upon sampling of the cervix, and maintain that orientation upon subsequent transfer of cell clusters to a receiving structure 101 which also includes a corresponding orientation mark 108 as shown in
The cell collector 100 can have a number of different configurations as long as it is capable of collecting clusters of cells from both the endo- and ectocervices 56, 62 to ensure collection of cell clusters from the transition zone 58. In one embodiment, a combination of the material of the collector surface 104, the texture of the collector surface 104, and the use of expansion and rotation of the collector surface during collection facilitates the collection of the clusters of cells.
A. Collection
With reference now to FIGS. 2A-C, details of a cervical cell collector assembly 150 embodying the concepts of the invention are illustrated. The collector assembly 150 includes a hollow tube 200 that is detachably connected to an expandable collection tip 201. The tube 200 is made from, for example, plastic or cardboard. The expandable tip 201, which is also the cell collection region of the collector 150, is a resiliently flexible structure that is made of an elastomeric material, for example a thermoplastic elastomer alloy such as Versaflex® CL30 available from GLS Corporation of McHenry, Ill. The expandable tip 201 preferably has a texture that enhances the ability of the collector to collect clusters of cells from the transition zone 58 upon expansion and rotation of the tip 201. For example, the tip 201 can have a texture of MT-11010. Other elastomeric materials could be used for the tip 201, for example microporous polyvinyl acetate, nitrile rubber, nitrile foam, urethane foam, silicone rubber, latex rubber, polyurethane and other elastomers having low durometer, high percent elongation and adequate texture to enhance collection of cell clusters.
The tube 200 is generally hollow from one end 202 to the other end 204, with the end 202 of the tube 200 being open. With reference in particular to
The probe 306 can have a diameter of approximately 2 mm and project beyond the end of the expander probe 305 a distance between approximately 8 to 10 mm. The body of the expander probe 305 forward of the shoulder 324 can have a diameter of approximately 6 mm, while the shoulder 324 has a diameter of approximately 10 mm.
A coil spring 326 is disposed between the shoulder 324 and the end of the outer casing 307 for biasing the expander probe 305 to the left in
The outer tube 307 also includes a tube lock 309. The tube lock 309 comprises a resilient member fixed to the outer tube 307 that projects upwardly through an aperture 332 (see
Returning to
A handle 312 is fixed to a support 313 that is connected to the inner tube 308. The handle 312 is rotatably secured to the support 313 by a pivot 314 to allow the handle 312 to pivot between the position shown in
As best seen in
The user then pushes on the spring cap 311 with the thumb or other digit as shown in
During its movements, the expander probe 305 expands the tip region 210 of the expandable tip 201 into engagement with the endocervix 56. In addition, the shoulder 208 and/or transition section 212 of the expandable tip 201 compresses against the ecto-surface of the cervix 50. As a result, both endocervical and ectocervical cells, including cells from the transition zone 58, can be collected.
The expandable tip 201 is also rotated during collection in order to collect clusters of cells from the transition zone by shearing cell clusters from the transition zone 58 assisted by the texture of the tip 201. The tip 201 is rotated, for example, twenty to thirty degrees. The tip 201 can be rotated by the user manually rotating the handle assembly 303 and the collector assembly 150 connected thereto. Alternatively, the tip 201 can be rotated using a suitable mechanical rotation mechanism which causes rotation of the tip 201 once the tip region 210, shoulder 208 and transition section 212 of the tip 201 are expanded by the handle assembly 303 into contact with the endo- and ecto-cervices.
An example of a mechanical rotation mechanism is illustrated in FIGS. 20A-C.
A gripping sleeve 258 is slidably disposed on the portion 252 and the portion 254 over where the portions 252, 254 connect. Helical teeth (not shown) are disposed on the inside surface of the sleeve 258 for engagement with the teeth 256 on the portion 254.
During use of the assembly 250, after mounting the collector 150 onto the handle assembly 250, as the user inserts the probe, the probe 305 (shown in FIGS. 20A-C) is moved forward, causing the tip 201 to expand (
After insertion, and expansion and rotation to achieve cell cluster collection, the pressure is released and the return spring brings the mechanism back to the original position. The tube lock 309 is depressed and the cervical cell collector 150 is then detached.
The assembly 400 also includes a rear tube 408 having a front end thereof received within the rear end of the tube 402. A slot 410 is formed in the rear tube 408 and a button 412 is slideably disposed in the slot 410. The button 412 is connected to a projection 414 disposed within the slot 406 of the front tube 402.
The button 412 is illustrated in
Once the button 412 is pushed all the way forwardly and the collection tip expanded, the tip is then rotated. The tip can be manually rotated, as discussed above, by manually rotating the rear tube 408. Alternatively, a suitable mechanical rotation mechanism can be provided for rotating the collection tip.
B. Transfer
After collection, the cell collector assembly 150 is mounted on a transfer device for use in transferring cell clusters from the tip 201 to a receiving structure for subsequent analysis of cell clusters. Examples of suitable receiving structures include a slide, a petri dish, and other structures to which cell clusters may be transferred for subsequent analysis of the cell clusters. The transfer device is constructed so that transfer occurs at equal pressures from receiving structure to receiving structure. Further, the surface of the receiving structure has greater adhesiveness than the surface of the tip 201 containing cell clusters to enhance the transfer of cell clusters from the tip to the receiving structure. When the receiving structure is a slide, the slide can be provided with a coating that results in the greater adhesiveness.
The tip 201 of the collector assembly 150 is preferably inflated using air during transfer. When the tip 201 is made from a thermoplastic elastomer alloy such as Versaflex® CL30, the elastomer allows uniform expansion of the tip during inflation. During inflation for transfer, the tip region 210 and the transition section 212 substantially go away (see
After transfer, the tip 201 can be removed from the tube 200 and put into a container with preservative to preserve remaining cell clusters on the tip 201. The tube 200 can then be discarded or connected to a new tip 201 for further collections. If the tip 201 does not need to be preserved, the tip 201 can be discarded.
FIGS. 7A-K illustrate the concepts of cell cluster transfer using the cell collector 150, with colored marker and marking fluid simulating collected clusters of cells.
The collector 150 is placed on the device 704 such that the tip 201 faces a receiving structure in the form of a coated slide 703 placed on the bottom of the transfer device 704. The device 704 includes a clamp mechanism 705 that clamps the tube 200 and holds the tube 200 in place. The transfer device 704 also includes an air cylinder device 701 that is configured to pump air into the collector 150 in order to inflate the tip 201. A handle 702 is pivotally connected to the transfer device 704 and a rod 706 extends from the handle into the air cylinder device 701 for actuating a piston within the air cylinder device 701. As the user pushes down on the handle 702, the piston in the air cylinder device 701 is actuated to force air into the collector 150 through the tube 200 and into the tip 201 in order to inflate the tip (see
Once the tip 201 is inflated, a handle 708 connected to the device 704 is rotated. Rotation of the handle 708 causes the collector mount mechanism, including the collector assembly 150 mounted thereto, to move towards the slide 703 similar to a drill press. Eventually, the inflated tip is pressed down onto the slide 703, similar to the manner shown in
The mounting pulley 1604 includes a turntable 1608 having a handle 1610 and a support surface for receiving a microscope slide 1609. The slide 1609 is locked in place on the support surface using a suitable fixation mechanism, for example clamps. The turntable 1608 is rotatably mounted on a support plate 1611 to enable the turntable 1608 to rotate using the handle 1610. A support arm 1607 is pivotally connected to the plate 1611 by a pivot 1612, and the mounting arm 1613 extends from the support arm 1607. In addition, an air pump 1650 is connected to the support arm 1607 and is fluidly connected to the rear end of the mounting arm 1613 for pumping air into the mounting arm 1613 for inflating the tip 201. The air pump 1650 could be motor driven or driven manually by the user.
After collection, the collector is mounted on the mounting arm 1613 and locked in place (
Once the tip 201 is rotated down into engagement with the slide 1609, the support arm 1607 is locked to retain the tip 201 in contact with the slide 1609. The turntable 1608 is then rotated using the handle 1610. A drive mechanism is connected between the turntable 1608 and the mounting arm 1613, which is rotatably mounted on the support arm 1607, to cause rotation of the mounting arm 1613 and the collector 150 fixed thereto. The drive mechanism is configured such that once the collector tip 201 makes one full revolution, a spring in the turntable 1608 returns the mechanism back to the original position.
As shown in
C. Analysis
The cells and cell clusters transferred onto slide 101 as shown in
In order to label the cells and cell clusters, staining reagents including one or more molecular probes that react with a biomarker characteristic of dysplastic cervical epithelium could be used. The biomarkers that can be assessed include proteins, especially modified or activated forms of molecules expressed by proliferating cells. FIGS. 9A-C illustrate one example, where cervical cells, treated with a M344, an inhibitor of histone deacetylase which causes imbalanced cell cycles in neoplastically transformed cells, have been stained with a protein expressed in proliferating cells, phosphorylated ribosomal protein S6 (
Other biomarkers that can be used include nucleic acids, messenger RNA molecules for genes whose expression is enhanced in dysplastic cervical cells, lipids and glycosylated forms of proteins and lipids. The functions of these target biomolecules in proliferating and dysplastic cells can include intracellular signal transduction receptors (e.g., mitogen-activated protein kinases), structural proteins (e.g., cytokeratins), and nuclear proliferation-related gene products (e.g. Ki-67). The expression of these proteins can be a function of, for example, aberrant growth or apoptosis.
The manner in which the staining reagents are applied and detected in order to ascertain the expression of such biomolecules can include modification of antibody and nucleic acid probes with fluorophores (e.g. FITC), reactive tags (e.g. biotin), or direct conjugation of the molecule with a reporter molecule (e.g. horse radish peroxidase). Detection of these probes can be directly (e.g. by epifluorescent illumination) through the reaction with an enzymatic reporter molecule (e.g. streptavidin-conjugated alkaline phosphatase) and/or addition of precipitating substrates (e.g. nitro blue tetrazolium and bromochloroindolyl phosphate) for a calorimetric readout.
In order to recognize the presence of groups of dysplastic cells indicative of a cervical intraepithelial lesion, some manner of counterstain can be employed. This can be achieved using reagents currently employed in immunocytochemistry and immunohistochemistry to facilitate the visualization of cells (e.g. methyl green or hematoxylin), reagents reacting with a major cellular feature (e.g. phalloidin), or the reagents used to develop what is commonly termed a Pap stain.
A scanning device is subsequently used to measure the intensity of the individual signals from the appropriately detected probes and determine how the ratio of these signals varies across the collected and stained sample. The scanning and analysis are integrated over an area approximating the smallest preneoplastic lesion that is morphologically apparent to a clinician and which can be confirmed by histology or immunohistochemistry. The scanning device may be automated to permit multiple slides to be analyzed and the necessary analytic software can be either resident in the scanner or present on an external computer.
A cantilevered two-axis manual stage 1010, with a slide holder 1004 connected thereto, allows for the positioning of a slide between the magnifier and the illuminator. A differential 4-bar linkage 1012 is provided to allow for both coarse and fine slide positioning under the magnifier. The linkage 1012 is connected to a stage positioner 1018 that includes a joystick 1014 and lock 1016. A slider 1008 containing excitation and emission filters is provided to allow the specimen to be viewed in both white light and fluorescence. The slider 1008 is inserted between the planar illuminator and the slide holder. The manual device 1000 could also have a focusing nob to allow the user to adjust the resolution of the magnifier 1002.
A battery or wall wart can be used to power the illuminator. The illumination provided from the illumination unit 1006 will depend on the excitation light intensity needed to saturate the fluorophore used and the emission intensity produced by a positive cell cluster. Exemplary values include a dye with an absorption (excitation) maximum of 495 nm and emission maximum of 519 nm, or absorption at 590 nm with emission at 617 nm.
A taut-band drive and a lead screw drive 1114 driven by a motor 1116 are two examples of devices that would could be employed as a shuttle 1120. The shuttle 1120 rides on a linear bearing 1118. The elevators 1106, 1108 are one example of a moving belt design. In another example, the elevators could have a vertical walking beam design. The choice of elevator is dependent on packaging constraints and on throughput/batch size requirements. The scan time will depend upon light levels and the specific CIS used.
The CIS will also be responsible for reading barcode data from each slide. The barcode will include patient demographic data that can be printed in reports. Providing barcode data will decrease errors due to manual handling. Also, positive sample ID is mandatory for CLIA compliance.
A typical CIS reader has the ability to capture the barcode and decoding software (e.g. 8-10 characters of Code 128). A 200 DPI CIS (e.g. P1216MC-DR from Peripheral Imaging Corporation) can be used in the system. If there is a requirement for a specific wave length and gray scale, then it is contemplated that other CIS modules can be used. 200 DPI and higher monochrome and color CIS modules are available from numerous suppliers. If necessary, the CIS module can be modified for the particular application. For instance, it might be desirable to add wavelength selection filters. It also may also be desirable to remove the cover glass or go with a fractional pitch GRIN lens bar. It also may be desirable to use two monochrome CIS modules, one for each color, rather than cleaning up the spectral responses in a single color module. Again, the illumination provided by the CIS will depend on the excitation light intensity needed to saturate the fluorophore used and the emission intensity produced by a positive cell cluster. Exemplary values include a dye with an absorption (excitation) maximum of 495 nm and emission maximum of 519 nm, or excitation at 590 nm with emission at 617 nm.
The automated unit can be controlled in one example with a single board computer (SBC) that is specifically designed for use in embedded systems rather than in desktop/laptop applications. Exemplary SBC's include but are not limited to those produced by Sharp, Atmel and Auron. The SBC will also be responsible for data acquisition/processing and printing. The SBC will have to be programmed, in a known manner, for the specific application of controlling the automated system and acquiring and processing the data received from the CIS. If significant user interface interaction is required, such as showing the results of all samples in a window, complex printing, or storage of raw data, the data could be transferred to a personal or mainframe computer by using a USB interface, or similar mechanism of data transfer.
The power source used for the automated system can take many forms. In one example, rechargeable batteries could be used. The power requirement of a processor and LCD display at 5 VDC is ˜450 mA. Such a power requirement could be met with NiMH type batteries. For instance, four 3500 mAHr batteries would provide 7 hrs of operation on a new battery. If AA batteries, in the 1500 mAHr range were used, then 3 hours of operation would be provided on a new battery.
Finally, it is contemplated that a “lite” version of the automated system could also be effected. Such a lite version would include a LCD screen, a one axis stage, a CIS sensor, and scaled down processing capability. The user would position the slide under the CIS. The user could then push a button to acquire the data and the data would then be displayed on the LCD screen.
With reference now to
The cell sampling region 12 can be a resiliently flexible structure that is made of a suitable elastomeric material such as microporous polyvinyl acetate, thermoplastic elastomer, nitrile rubber, nitrile foam, urethane foam, silicone rubber, latex rubber, polyurethane or any material having suitable low durometer, high percent elongation and surface qualities.
As suggested by
Contact and rotation of the cell sampling member 12 against the surfaces of the cervical os and canal 100 causes exfoliated cervical cells to adhere to the exterior surface of the cell sampling member. Retraction of the pusher 232 withdraws the tip expander 16 from the tip of the cell sampling member 12, thus allowing the cell sampling member to return to its initial extended state. The cervical cell collector 10 may then be removed from the cervical canal 100 and vagina and the cells collected on the surface of the cell sampling member prepared for evaluation.
The cells captured on the cell sampling region 12 may be prepared for evaluation by several means. One such means is the preparation of a suspension of the capture cells in a suitable preservative medium by immersing and, preferably, agitating the cell collection surface in the preservative medium. The cells of the resulting suspension may be deposited upon a microscope slide or similar surface in the manner of a conventional monolayer cell preparation and stained and evaluated in accordance with established methods. Alternatively, the suspended cells may be evaluated using a flow cytometer.
Another means of preparing the captured cells for evaluation is schematically illustrated in
As shown in
The coverslipped slide is reviewed using the appropriate illumination. It is scrutinized to determine whether there is a localization of signal in one area of the cervical sample. The location of the candidate lesion is noted with respect to a map of the cervix indicating the locations of the collected cells.
Cells of the ecto- and endocervices are sampled using a collector with the characteristics described above. The sample may be collected by a physician or health care worker. Alternately, it should be possible to train women to collect their own samples to achieve the purposes of the cervical analysis system.
While the invention has been described in conjunction with a preferred embodiment, it will be obvious to one skilled in the art that other objects and refinements of the present invention may be made with the present invention within the purview and scope of the present invention.
The invention, in its various aspects and disclosed forms, is well adapted to the attainment of the stated objects and advantages of others. The disclosed details are not to be taken as limitations on the invention.
This application claims the benefit of U.S. Provisional Application No. 60/642,008 filed Jan. 6, 2005; U.S. Provisional Application No. 60/681,901 filed May 17, 2005; U.S. Provisional Application No. 60/686,150 filed Jun. 1, 2005; U.S. Provisional Application No. 60/708,150 filed Aug. 15, 2005; U.S. Provisional Application No. 60/729,854 filed Oct. 25, 2005; and U.S. Provisional Application No. 60/729,857 filed Oct. 25, 2005. Each of the above-referenced applications is incorporated herein by reference in their entirety.
Number | Date | Country | |
---|---|---|---|
60642008 | Jan 2005 | US | |
60681901 | May 2005 | US | |
60686150 | Jun 2005 | US | |
60708150 | Aug 2005 | US | |
60729854 | Oct 2005 | US | |
60729857 | Oct 2005 | US |